Alphyn Biologics, Inc.
PrivateLast Round
Series B
Dec 12, 2025
Est. Valuation
$42.8M
Total Funding Raised
$31.78M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Alphyn Biologics, Inc. is a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics for severe and prevalent skin diseases based on its proprietary Zabalafin Platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alphyn Biologics, Inc. Comparables
Compare Alphyn Biologics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Concerto Biosciences | 82% | |
| Xantho Biotechnology Co., Ltd. | 79% | |
| MatriSys Bioscience | 78% |
Alphyn Biologics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 12, 2025 | ||||
| Series B | Jan 4, 2023 | ||||
| Series A | Sep 15, 2022 | ||||
| Seed | Jun 30, 2021 | ||||
| Seed | Mar 1, 2020 |
Alphyn Biologics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Serial Stage Venture Partners | Series B, Series A |
| QCA Ventures | Series B, Series A |
| VisionTech Partners | Series B |
| QCA Ventures | Series B |
| Angel Physicians Fund | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 255% MoM, from 209 to 741.
- Apr 19, 2026
Monthly visitors grew 618% MoM, from 285 to 2K.
Alphyn Biologics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alphyn Biologics, Inc.'s valuation, stock price, and market status.
Is Alphyn Biologics, Inc. a public or private company?
Alphyn Biologics, Inc. is a private company.
What is the current stock price of Alphyn Biologics, Inc.?
Alphyn Biologics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Alphyn Biologics, Inc. worth (valuation)?
Alphyn Biologics, Inc.'s valuation is estimated at $42.8M based on funding round data.
Can I buy Alphyn Biologics, Inc. stock?
Alphyn Biologics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alphyn Biologics, Inc.'s last funding round?
Alphyn Biologics, Inc.'s most recent funding round was Series B on January 4, 2023.
Who are the main investors in Alphyn Biologics, Inc.?
Key investors in Alphyn Biologics, Inc. include QCA Ventures, QCA Ventures.
Will Alphyn Biologics, Inc. IPO soon?
No public IPO plans have been announced for Alphyn Biologics, Inc..
How can I track Alphyn Biologics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alphyn Biologics, Inc.'s secondary market activity and sign up for updates.